Immunomodulatory Peptides for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy, often result in significant side effects and resistance issues, highlighting the need for safer and more effective therapies that leverage the mammalian immune system to combat cancer.
Innovation Solution
Development of peptides and nucleic acid constructs that modulate the activity of target proteins such as CCR9, CXCR3, and CXCR4, administered alone or in combination with other therapies, to enhance immunotherapy and treat various types of cancer by modulating cytokine production and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat cancer, then cancer cells can be targeted based on proliferative profiles, but significant side effects occur in normally proliferative tissues such as gastrointestinal tract and bone marrow
Solution Approach 1:
The patent uses immune system components (dendritic cells, T-cells, cytokines) as intermediaries to indirectly target cancer cells. Instead of directly attacking rapidly dividing cells with chemotherapy, the invention stimulates the immune system to recognize and eliminate tumor cells through antigen presentation and immune response activation, thereby sparing normal proliferative tissues from direct toxic damage
Solution Approach 2:
The patent replaces the mechanical/cellular toxicity mechanism of chemotherapy with a biological signaling mechanism. Rather than using cytotoxic drugs that physically damage dividing cells, the invention employs peptides and nucleic acids that modulate immune system signaling pathways (cytokine production, cell activation), allowing for more selective and controllable cancer cell destruction
2Reliability
If chemotherapy agents are developed to improve cancer treatment, then treatment effectiveness increases, but resistance issues and non-specific toxicity develop
Solution Approach 1:
The patent enables the patient's own immune system to perform the cancer-fighting function. By introducing immunostimulatory peptides and nucleic acids, the invention activates the body's natural immune mechanisms (dendritic cell maturation, T-cell activation, cytokine production) to autonomously recognize and eliminate cancer cells, reducing dependence on external chemotherapeutic agents and their associated resistance problems
Solution Approach 2:
The patent changes the fundamental parameters of cancer treatment from direct cytotoxicity to immunomodulation. By altering the mechanism of action from chemical cell damage to biological signal transduction, the invention achieves cancer cell killing through amplified immune responses while reducing non-specific toxicity and tumor resistance that characterize traditional chemotherapy
Data Source
AI summary
The disclosure provides peptides, pharmaceutical compositions, and methods of producing thereof. Such peptides can be useful, for example, in treating various human diseases such as immunological diseases or cancers. In some embodiments, the peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system.